赛伦生物(688163) - 2021 Q4 - 年度财报

Financial Performance - The company plans to distribute a cash dividend of RMB 9.00 per 10 shares, totaling RMB 97,398,000, which represents 127.35% of the net profit attributable to shareholders for 2021[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 208,693,627.46, representing a 12.47% increase compared to CNY 185,562,793.03 in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 76,482,795.73, which is a 21.07% increase from CNY 63,173,802.30 in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 69,513,945.85, reflecting a 23.06% increase from CNY 56,488,609.44 in 2020[22]. - The basic earnings per share for 2021 was 0.94 yuan, representing a 20.51% increase from 0.78 yuan in 2020[23]. - The weighted average return on equity increased to 23.08%, up 1.94 percentage points from 21.14% in 2020[23]. - The total assets at the end of 2021 were CNY 402,891,055.95, which is a 29.07% increase from CNY 312,148,232.39 at the end of 2020[22]. - The net assets attributable to shareholders increased by 25.47% to CNY 369,629,071.96 at the end of 2021, compared to CNY 294,606,422.89 at the end of 2020[22]. - The cash flow from operating activities for 2021 was CNY 92,288,488.20, a decrease of 6.17% compared to CNY 98,354,730.48 in 2020[22]. Research and Development - The company is focused on the development of new biological emergency rescue drugs under the ATS project[13]. - The company aims to enhance its production processes to achieve higher purity and quality in its products[13]. - The company is actively involved in the research and development of immunoglobulin products for various therapeutic applications[13]. - Research and development expenses accounted for 12.34% of operating revenue, an increase of 0.21 percentage points from the previous year[24]. - The total R&D investment for the year was approximately ¥25.76 million, an increase of 14.42% from the previous year, with R&D expenses accounting for 12.34% of total revenue[67]. - The company has developed core proprietary technologies for the safe and effective production of emergency treatment drugs, including toxin proteomics research and antigen purification technology[61]. - The company has established a structured governance framework to ensure effective decision-making and protect shareholder interests[137]. - The company has 12 ongoing research projects, including the development of antivenoms and immunoglobulins, with expected total investments ranging from 620.00 million RMB to 8,000.00 million RMB[69]. - The company has received 4 new invention patents during the reporting period, bringing the total number of granted patents to 12[65]. Market Position and Strategy - The company is committed to expanding its market presence and enhancing its product offerings in the biopharmaceutical sector[13]. - The biopharmaceutical market in China is expected to reach RMB 1,319.8 billion by 2030, with a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030[48]. - The company is currently the only producer of antivenom serum and equine tetanus immunoglobulin in China, holding a unique market position[52]. - The company aims to become a leading enterprise in the field of biotoxin and biosafety drug development, focusing on the research and development of various types of antivenoms[38]. - The company has established a comprehensive marketing team covering the entire industry chain from research and development to production and sales[38]. - The company is focusing on strategic acquisitions to enhance its technology capabilities, targeting two potential companies by Q2 2024[151]. Operational Risks and Governance - The company has detailed various operational risks in the report, which investors should review[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors[6]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with a majority of directors being unable to ensure the accuracy and completeness of the annual report[8]. - The company has established a comprehensive internal control system to ensure effective governance and management, covering major investments, related transactions, and external guarantees[174]. - The company has a solid governance structure involving the shareholders' meeting, board of directors, independent directors, supervisory board, and senior management[174]. Environmental and Social Responsibility - The company is classified as a key pollutant discharge unit, implementing various measures to manage waste gas and wastewater effectively[178]. - The company has established an environmental monitoring plan, ensuring that all pollution indicators meet the required standards through third-party testing[183]. - The company has implemented automatic online monitoring for wastewater discharge, ensuring real-time compliance with environmental standards[187]. - The company has actively improved product quality standards, adding new quality control projects for its anti-five-step snake venom serum[37]. - The company has established emergency response plans for environmental incidents, with regular training for employees to enhance crisis management capabilities[182]. - The company actively participates in social responsibility initiatives, including building a rescue network for snakebite patients[177]. Employee and Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 6.1287 million[154]. - The company has implemented a competitive and incentive-based salary policy to enhance employee motivation and performance[166]. - Employee benefits include free lunch, dormitory accommodations, free shuttle service, high-temperature allowances, annual health check-ups, holiday benefits, birthday benefits, and special benefits for female employees[167]. - The company emphasizes employee training across various aspects, including professional skills and knowledge, to enhance overall competency and retain talent[168]. - The company employed a total of 295 staff members, with 230 in the parent company and 65 in major subsidiaries[165]. Product Development and Quality Control - The company has established a comprehensive quality management system in compliance with GMP, ensuring product quality throughout the entire lifecycle[200]. - The company has a robust after-sales service system, including regular follow-ups and a user complaint management procedure[199]. - All sales drugs have obtained necessary registration certificates, with no administrative penalties due to quality issues reported during the period[200]. - The company has implemented a supplier evaluation and approval system to ensure quality and compliance of raw materials and components[199]. - The company has upgraded the production process of traditional tetanus antitoxin to improve purity and reduce adverse reaction rates, which is a necessary trend in the industry[60].